Results 21 to 30 of about 69,107 (331)

Total tissue lactate dehydrogenase activity in endometrial carcinoma [PDF]

, 2008
Lactate dehydrogenase (LDH) is essential for continuous glycolysis necessary for accelerated tumor growth. The aim of this study was to reconsider if assay of total tissue activity of this enzyme could be useful as marker for endometrial carcinoma (EC ...
Abramić, Marija, Babić, Damir, Ilić-Forko, Jadranka, Osmak, Maja, Šimaga, Šumski   +4 more
core   +1 more source

Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase‐4 inhibitors in treatment‐naïve patients with type 2 diabetes in Japan

Journal of Diabetes Investigation, 2020
Japan's guidelines emphasize tailored therapy, but do not guide physicians on the use of a specific regimen in drug‐naive patients. The role of long‐term initial therapy could be important in key elements of diabetes treatment, such as continuation of ...
Takeshi Horii, Makiko Iwasawa, Jyunichi Shimizu, Koichiro Atsuda   +3 more
doaj   +1 more source

An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease

SAGE Open Medicine, 2016
Objective: This updated meta-analysis determines the effect of dipeptidyl peptidase-4 inhibitors on glycemic and tolerability outcomes in patients with type 2 diabetes mellitus and chronic kidney disease with glomerular filtration rate of ⩽60 mL/min or ...
Devada Singh-Franco, Catherine Harrington, Eglis Tellez-Corrales   +2 more
doaj   +1 more source

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study

BMC Endocrine Disorders, 2021
Background Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid.
Vaia Lambadiari, Aikaterini Kountouri, Foteini Kousathana, Emmanouil Korakas, Georgios Kokkalis, Sofia Theotokoglou, Lina Palaiodimou, Pelagia Katsimbri, Ignatios Ikonomidis, Konstantinos Theodoropoulos, Evangelia Papadavid   +10 more
doaj   +1 more source

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources

Synthesis of new DPP-4 inhibitors based on a novel tricyclic scaffold [PDF]

, 2015
A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogues of biologically active molecules will be discussed.
Biftu T., Borne R. F., Chutian S., Drucker D. J., Drucker D. J., Hawkins P. C. D., Herman G. A., Juillerat-Jeanneret L., Kim D., Nauck M., Occhiato E. G., Orsakov C., Schwehm C., Thomsen I., Thornberry N. A.   +14 more
core   +3 more sources

Extra virgin olive oil use is associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects [PDF]

, 2015
Extra virgin olive oil (EVOO) is a key component of the Mediterranean diet and seems to account for the protective effect against cardiovascular disease.
ANGELICO, Francesco, BARTIMOCCIA, SIMONA, CANGEMI, ROBERTO, CARNEVALE, Roberto, LOFFREDO, Lorenzo, MONTICOLO, Roberto, NOCELLA, CRISTINA, PASTORI, DANIELE, Petruccioli, A, PIGNATELLI, Pasquale, VIOLI, Francesco   +10 more
core   +1 more source

The purification and characterisation of novel dipeptidyl peptidase IV-like activity from bovine serum [PDF]

, 2004
The discovery of a potentially novel proline-specific peptidase from bovine serum is presented which is capable of cleaving the dipeptidyl peptidase IV (DPIV) substrate Gly-Pro-MCA.
Abbott, Birney, Cunningham, De Meester, De Meester, Duke-Cohan, Duke-Cohan, Duke-Cohan, Durinx, Gilmartin, Hegen, Hopsu-Havu, Huang, Iwaki-Egawa, Kin, Laemmli, Malik, Mentlein, Mentlein, Ohkubo, Ohnishi, Pineiro-Sanchez, Scanlan, Schon, Sedo, Sedo, Shibuya-Saruta, Smith, Stockel-Maschek, Underwood, Yaron, Yoshimoto   +31 more
core   +1 more source

Dipeptidyl peptidase-4 inhibitor-related renal disease

Journal of Diabetes and its Complications, 2023
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used to treat type 2 diabetes (T2D). Lowering blood glucose is expected also to reduce the progression of diabetic nephropathy. We experienced a patient with T2D who achieved good glycemic control with a DPP-4 inhibitor but experienced rapid deterioration of renal function.
Atsuhiko, Suenaga, Naoki, Sawa, Yuki, Oba, Daisuke, Ikuma, Akinari, Sekine, Eiko, Hasegawa, Hiroki, Mizuno, Tatsuya, Suwabe, Sara, Ikeda, Tetsuro, Tsujimoto, Kei, Kono, Yukako, Shintani-Domoto, Keiichi, Kinowaki, Kenichi, Ohashi, Motoaki, Miyazono, Yutaka, Yamaguchi, Yoshifumi, Ubara   +16 more
openaire   +2 more sources

Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration. [PDF]

, 2015
The gut incretin glucagon-like peptide-1 (GLP-1) and the intestinotropic hormone GLP-2 are released from enteroendocrine L cells in response to ingested nutrients.
Abe, Yosuke, Akiba, Yasutada, Fujiwara, Kaori, Fukunishi, Shinya, Higuchi, Kazuhide, Iguchi, Munetaka, Inoue, Takuya, Ishida, Kumi, Kakimoto, Kazuki, Kaunitz, Jonathan D, Masuda, Daisuke, Narabayashi, Ken, Nouda, Sadaharu, Okada, Toshihiko, Sakanaka, Taisuke, Takeuchi, Toshihisa, Umegaki, Eiji, Yorifuji, Naoki   +17 more
core   +1 more source